Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network

Author:

Burnett-Hartman Andrea N.1,Udaltsova Natalia2,Kushi Lawrence H.2,Neslund-Dudas Christine3,Rahm Alanna Kulchak4,Pawloski Pamala A.5,Corley Douglas A.2,Knerr Sarah6,Feigelson Heather Spencer1,Hunter Jessica Ezzell7,Tabano David C.1,Epstein Mara M.8,Honda Stacey A.9,Ter-Minassian Monica10,Lynch Julie A.11,Lu Christine Y.12

Affiliation:

1. Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO

2. Kaiser Permanente Northern California, Oakland, CA

3. Henry Ford Health System, Detroit, MI

4. Genomic Medicine Institute, Geisinger, Danville, PA

5. HealthPartners Institute, Bloomington, MN

6. University of Washington and Kaiser Permanente Washington Health Research Institute, Seattle, WA

7. Kaiser Permanente Northwest, Portland, OR

8. University of Massachusetts Medical School, Worcester, MA

9. Kaiser Permanente Hawaii, Honolulu, HI

10. Kaiser Permanente Mid-Atlantic States, Rockville, MD

11. Department of Veterans Affairs Salt Lake City Health System, Salt Lake City, UT

12. Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA

Abstract

PURPOSETo evaluate health care systems for the availability of population-level data on the frequency of use and results of clinical molecular marker tests to inform precision cancer care.METHODSWe assessed cancer-related molecular marker test data availability across 12 US health care systems in the Cancer Research Network. Overall, these systems provide care to a diverse population of more than 12 million people in the United States. We performed qualitative analyses of test data availability for five blood-based protein, nine germline, and 14 tissue-based tumor marker tests in each health care system’s electronic health record and tumor registry using key informants, test code lists, and manual review of data types and output. We then performed quantitative analyses to estimate the proportion of patients with cancer with test utilization data and results for specific molecular marker tests.RESULTSHealth systems were able to systematically capture population-level data on all five blood protein markers, six of 14 tissue-based tumor markers, and none of the nine germline markers. Successful, systematic data capture was achievable for tests with electronic data feeds for test results (blood protein markers) or through prior manual abstraction by tumor registrars (select tumor-based markers). For test results stored in scanned image files (particularly germline and tumor marker tests), information on which test was performed and test results was not readily accessible in an electronic format.CONCLUSIONEven in health care systems with sophisticated electronic health records, there were few codified data elements available for evaluating precision cancer medicine test use and results at the population level. Health care organizations should establish standards for electronic reporting of precision medicine tests to expedite cancer research and facilitate the implementation of precision medicine approaches.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3